]>

IRCT20210515051296N1 IRCT 2021-07-11 Qazvin University of Medical Sciences Effect of cupping on pulmonary symptoms of COVID-19 The effect of cupping therapy on blood oxygen level in patients with coronavirus 2 (SARS-CoV-2) infection with pulmonary involvement 2021-07-21 anticipated 55 Complete https://irct.ir/trial/56431 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Before intervention, each patient selects one of the 55 envelopes that contain the codes 001 to 055, then by having the selected code and using the output table of Block randomization statistical software, it is determined the patient in which group: intervention or controls. 3 COVID-19. Intervention 1: Intervention group: Patients in this group receive the treatment of COVID-19 according to the protocol of the Ministry of Health, in addition, they should receive cupping therapy using special disposable plastic cups for cupping therapy, for each patient, for 14 days, once a day for 15 to 20 minutes in the back of the chest. Intervention 2: Control group: The control group will be received only the prescribed medications for the treatment of COVID-19 according to the protocol of the Ministry of Health. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no more information.

public Mahyar Seddighi

Buali Sina Medical Center, Buali Street, Qazvin

Qazvin Iran (Islamic Republic of) 3416586165 +98 28 3333 2930 mahyarseddighi@gmail.com Qazvin University of Medical Sciences scientific Mahyar Seddighi

Buali Sina Medical Center, Buali Street, Qazvin

Qazvin Iran (Islamic Republic of) 3413786135 +98 28 3333 2930 mahyarseddighi@gmail.com Qazvin University of Medical Sciences Iran (Islamic Republic of) Patients 18 to 65 years Resident of Qazvin Willingness to participate in the research project and complete the consent form Presence of typical evidence on lung CT-Scan or positive specific RT-PCR test from oropharyngeal secretions Presence of clinical criteria for hospitalization (fever above 38 ° C or severe cough or shortness of breath or respiratory rate greater than 24 per minute or oxygen saturation less than 93%) 18 years 65 years Both Having a history of coagulation diseases, obesity, deep vein thrombosis Have a history of vertebral fracture or disc herniation Patients during pregnancy, lactation, and menstruation Patients with heart failure Patients with chronic renal failure cancer patients Patients with defective immune system or Patients receiving corticosteroids Existence of open wound at the site of cupping U07.1 Probable COVID-19 Treatment - Devices Treatment - Devices Intervention group: Patients in this group receive the treatment of COVID-19 according to the protocol of the Ministry of Health, in addition, they should receive cupping therapy using special disposable plastic cups for cupping therapy, for each patient, for 14 days, once a day for 15 to 20 minutes in the back of the chest. Control group: The control group will be received only the prescribed medications for the treatment of COVID-19 according to the protocol of the Ministry of Health. Arterial blood oxygen saturation. Timepoint: At the beginning of the study (before the intervention) and the first to fourteenth days during cupping therapy. Method of measurement: Pulse oximetry. Muscular pain. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score. Headache. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score. Chest pain. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score. Number and severity of cough. Timepoint: At the beginning of the study (before the intervention) and then daily for 14 days from the beginning of cupping therapy to the end of cupping therapy. Method of measurement: By asking the patient and the Visual Analog Scale (VAS) score. Hemoglobin. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. ESR. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Sed rate device. LDH. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Device of utoanalyser. RDW. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. Platelet. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. WBC count. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. Lymphocyte Percentage. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. Neutrophil Percentage. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: CBC test. CRP. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Agglutination kit. Na. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Flame photometer. K. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Flame photometer. Blood Suger. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Device of utoanalyser. BUN. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Device of utoanalyser. Creatinin. Timepoint: At the beginning of the study (before the intervention) and every other day for 14 days from the beginning of cupping therapy to the end of cupping therapy for 7 days. Method of measurement: Device of utoanalyser. Qazvin University of Medical Sciences Approved 2021-02-08 Qazvin University of Medical Sciences Qazvin University of Medical Sciences, Shahid Bahonar Boulevard, Qazvin, Iran Qazvin Qazvin Iran (Islamic Republic of)